BNT162b2与mRNA-1273新冠疫苗加强针效果比较
该匹配队列研究基于英格兰OpenSAFELY-TPP平台,纳入3 237 918名已接种基础免疫的成人,比较BNT162b2与mRNA-1273加强针在接种后20周的有效性。结果显示mRNA-1273在预防SARS-CoV-2阳性检测和新冠住院方面较BNT162b2有轻微优势,新冠相关死亡罕见且组间差异无统计学意义。
要点
- mRNA-1273加强针较BNT162b2轻微降低SARS-CoV-2阳性检测风险(HR 0.95)。
- mRNA-1273加强针较BNT162b2轻微降低新冠住院风险(HR 0.89)。
- 新冠相关死亡罕见,两组差异无统计学意义(HR 0.83,95%CI 0.58-1.19)。
核心结论
- 在delta和omicro变异株流行期间,mRNA-1273加强针较BNT162b2在预防SARS-CoV-2阳性检测和新冠住院方面有轻微优势。
研究设计与样本
- 匹配队列研究,模拟比较效果试验,基于OpenSAFELY-TPP平台的初级保健、医院和新冠监测链接记录。
- 纳入3 237 918名成人,在2021年10月29日至2022年2月25日期间接种加强针,且基础免疫为BNT162b2或ChAdOx1。
- 每个疫苗组匹配1 618 959人,总随访64 546 391人周。
主要发现
- 接种后20周SARS-CoV-2阳性检测风险每1000人:BNT162b2为164.2(95%CI 163.3-165.1),mRNA-1273为159.9(95%CI 159.0-160.8),HR 0.95(95%CI 0.95-0.96)。
- 接种后20周新冠住院风险每1000人:BNT162b2为0.75(95%CI 0.71-0.79),mRNA-1273为0.65(95%CI 0.61-0.69),HR 0.89(95%CI 0.82-0.95)。
- 接种后20周新冠相关死亡风险每1000人:BNT162b2为0.028(95%CI 0.021-0.037),mRNA-1273为0.024(95%CI 0.018-0.033),HR 0.83(95%CI 0.58-1.19)。
- 亚组分析(基础免疫疫苗品牌、年龄、既往SARS-CoV-2感染、临床脆弱性)及delta和omicro变异株时期分别比较,相对获益相似。
临床怎么用
- 在选择加强针时,可告知mRNA-1273较BNT162b2在预防感染和住院方面有轻微额外获益,但绝对差异较小。
- 新冠相关死亡风险极低,两种加强针均有效,选择时应结合供应、可及性和个体情况。
局限性
- 观察性研究,尽管采用匹配设计,仍可能存在未测量混杂。
- 研究期间以delta和omicro变异株为主,结论外推至其他变异株需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the effectiveness of the BNT162b2 mRNA (Pfizer-BioNTech) and mRNA-1273 (Moderna) covid-19 vaccines during the booster programme in England. DESIGN: Matched cohort study, emulating a comparative effectiveness trial. SETTING: Linked primary care, hospital, and covid-19 surveillance records available within the OpenSAFELY-TPP research platform, covering a period when the SARS-CoV-2 delta and omicron variants were dominant. PARTICIPANTS: 3 237 918 adults who received a booster dose of either vaccine between 29 October 2021 and 25 February 2022 as part of the national booster programme in England and who received a primary course of BNT162b2 or ChAdOx1. INTERVENTION: Vaccination with either BNT162b2 or mRNA-1273 as a booster vaccine dose. MAIN OUTCOME MEASURES: Recorded SARS-CoV-2 positive test, covid-19 related hospital admission, covid-19 related death, and non-covid-19 related death at 20 weeks after receipt of the booster dose. RESULTS: 1 618 959 people were matched in each vaccine group, contributing a total 64 546 391 person weeks of follow-up. The 20 week risks per 1000 for a positive SARS-CoV-2 test were 164.2 (95% confidence interval 163.3 to 165.1) for BNT162b2 and 159.9 (159.0 to 160.8) for mRNA-1273; the hazard ratio comparing mRNA-1273 with BNT162b2 was 0.95 (95% confidence interval 0.95 to 0.96). The 20 week risks per 1000 for hospital admission with covid-19 were 0.75 (0.71 to 0.79) for BNT162b2 and 0.65 (0.61 to 0.69) for mRNA-1273; the hazard ratio was 0.89 (0.82 to 0.95). Covid-19 related deaths were rare: the 20 week risks per 1000 were 0.028 (0.021 to 0.037) for BNT162b2 and 0.024 (0.018 to 0.033) for mRNA-1273; hazard ratio 0.83 (0.58 to 1.19). Comparative effectiveness was generally similar within subgroups defined by the primary course vaccine brand, age, previous SARS-CoV-2 infection, and clinical vulnerability. Relative benefit was similar when vaccines were compared separately in the delta and omicron variant eras. CONCLUSIONS: This matched observational study of adults estimated a modest benefit of booster vaccination with mRNA-1273 compared with BNT162b2 in preventing positive SARS-CoV-2 tests and hospital admission with covid-19 20 weeks after vaccination, during a period of delta followed by omicron variant dominance.
引用
- Hulme WJ, Horne EMF, Parker EPK, et al. Comparative effectiveness of BNT162b2 versus mRNA-1273 covid-19 vaccine boosting in England: matched cohort study in OpenSAFELY-TPP. BMJ. 2023. PMID: 36921925. doi:10.1136/bmj-2022-072808
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。